The received positive results of efficiency and safety of a vaccine allow to recommend its application for children from 13-17 years, and it is possible and with 6-12 years. Clinical trials were conducted in 90 foci of the disease. In 48 of them, vaccination was carried out immediately after the diagnosis of fever, and in 42 – after 21 days. In the first group, no one fell ill, and the second fever was diagnosed in 16 people. In total, 7651 volunteers participated in the testing.
At this stage, the World Health Organization plans to use the vaccine to eliminate foci of infection, and not for preventive vaccinations. Caution in use is due to the fact that during the tests there was no placebo effect, which could slightly overestimate the effectiveness of rVSV-ZEBOV.